Role of biologic therapy in systemic autoimmune diseases;Papel de los fármacos biológicos en el tratamiento de las enfermedades autoinmunitarias

Medicina Clinica

Volumn 128, Issue 12, 2007, Pages 456-457

  Espinosa, Gerard ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; EDITORIAL; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL LITERATURE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 34247637131     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13100566     Document Type: Editorial

References (20)

1. García Hernández FJ, Ocańa Medina C, González León R, Garrido Rasco R, Colorado Bonilla R, Castillo Palma MJ, et al. Utilidad del rituximab en el tratamiento de pacientes con enfermedades sistémicas autoinmunitarias. Med Clin (Barc). 2007;12:458-62
2. Bongu A, Chang E, Ramsey-Goldman R. Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol. 2002;16:313-32.
3. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential target for mAb therapy. Curr Op Autoimmun. 2005;8:140-74.
4. Anolik JH, Aringer M. New treatments for SLE: cell-depleting and cytokine therapies. Best Pract Res Clin Rheumatol. 2005;19:859-78.
5. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Op Rheumatol. 2005:17:550-7.
6. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-20.
7. Cambridge E, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54:3612-22.
8. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-9.
9. Furie R, Stohl W, Ginzler E. Safety, pharmacokinetic and pharmacodynamic results of a phase I single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BlyS) in SLE patients. Arthritis Rheum. 2003;48:S377.
10. Daikh D, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4-Ig and cyclophosphamide. J Immunol. 2001;166:2913-6.
11. Sidiropoulos PI, Boumpas DT. Lessond learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus. 2004;13:391-7.
12. Smolen JS, Steiner G, Aringer M. Anti-cytokine therapy in systemic lupus erythematosus. Lupus. 2005:14:189-91.
13. Jayne D. What place for the new biologics in the treatment of necrotising vasculitides. Clin Exp Rheumatol. 2006;24 Suppl 41:1-5.
14. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:1116-7.
15. Bhatia A, Ell PJ, Edwards JCW. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64:1099-100.
16. Schmitt WH, Hagen EC, Neumann I, Flores-Suárez LF, Van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004;65:1440-8.
17. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosupression and immunoablation. Hematology. 2005;10:79-93.
18. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351-61.
19. Chan AT, Flossmann O, Mukhtyar C, Jayne DWR, Luqmani RA. The role of biologic therapies in the management of systemic vasculitis. Autoimmun Rev. 2006;5:273-8.
20. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296-304.